Turning Oncolytic Viruses Into Manufacturable Cancer Therapies

By Louisa Amoedo, Vice President of Operations

Raising viral yield is the easy part of oncolytic virus manufacturing. The harder task is keeping the properties that give the product its activity intact as a research process becomes a GMP one.

Written from a CDMO perspective, with a contribution from Louisa Amoedo, Vice President of Operations at Recipharm, this paper looks at three pressure points that tend to surface during scale-up: material and consumable choices, the stability of intermediates when operations stretch from hours to days, and analytical methods that are often product-specific and variable in ways that can mask or mimic process failure. It also considers how risk assessment and early regulatory dialogue can guide which changes are truly necessary.

Explore the paper to see how early decisions shape what happens later.